Introduction

Knee osteoarthritis is a widespread and often debilitating condition affecting many people across the UK. It gradually wears down the cartilage in the knee joint, causing pain, stiffness, and reduced mobility – all of which can seriously affect quality of life. As treatment options continue to develop, Arthrosamid has attracted growing attention as an injectable therapy that may offer relief. Yet despite its increasing popularity in private clinics, many wonder why Arthrosamid injections are not currently available on the NHS. This article explores the reasons behind this, offering clear insight into the complex process for approving new treatments in the public healthcare system.

Understanding Arthrosamid: Promise and Potential

Arthrosamid is an injectable hydrogel designed to cushion the knee joint and ease osteoarthritis pain. Unlike traditional treatments such as steroid or hyaluronic acid injections, Arthrosamid offers a fresh approach to improving joint comfort and function. It is already in use internationally and in private UK clinics, gaining a reputation as a promising option for patients with knee osteoarthritis.

As a recent review explains, “Polyacrylamide (PAAG) hydrogel is a novel compound that has recently become available in the UK market under the name Arthrosamid to treat osteoarthritis (OA)” (Cole et al., 2022). MSK Doctors provides expert support to patients exploring new therapies like Arthrosamid, with Professor Paul Lee – a nationally recognised specialist in musculoskeletal medicine – playing a key role in guiding patients and professionals alike. Still, despite its potential, Arthrosamid must undergo a formal evaluation to ensure it meets the NHS’s high standards for safety, effectiveness, and value before being widely available.

The NHS Approval Process for New Treatments

For a new treatment to be routinely offered on the NHS, it has to pass through a thorough, careful approval process. The National Institute for Health and Care Excellence (NICE) leads the assessment, scrutinising evidence about a product’s safety, how well it works, and whether it represents good value for money. This starts with reviewing clinical trial data and scientific research to establish benefits and risks.

Next, expert panels evaluate the evidence and consider how the treatment might fit into day-to-day patient care. There are also opportunities for public consultation before final recommendations are published. When it comes to knee osteoarthritis injections, this process is particularly detailed because of the many treatment choices already available. Although it can take time, NHS approval ensures that patients receive only effective and safe treatments while managing public resources responsibly.

Evidence, Cost-effectiveness, and Patient Safety Considerations

A key reason Arthrosamid isn’t yet on the NHS is the need for robust, long-term clinical evidence proving it delivers lasting benefits and maintains safety. Established treatments have years of supporting data, while newer options like Arthrosamid need more research to confirm consistent positive outcomes and identify any risks over time. For instance, a recent review highlighted “the efficacy of PAAG hydrogel at one year post injection” and noted “positive results for at least 2 years” (Cole et al., 2022).

Comparisons with other injection therapies provide helpful context: “iPAAG offers comparable short-term efficacy and modest advantage at 6 months. However, long-term superiority is limited. It may be a complementary option in individualized osteoarthritis management” (Aykaç et al., 2025). This suggests Arthrosamid has some benefits in the medium term but that its role in longer-term treatment remains to be fully understood.

Cost-effectiveness is equally important. With limited NHS budgets, treatments must provide strong value to be adopted. Patient safety is paramount, requiring careful monitoring of side effects and broad suitability. Laboratory studies add reassuring data, showing “no statistically significant effects on cell survival, non-apoptotic and apoptotic cell death, or the neurite network area” at tested concentrations of Arthrosamid (Walmod et al., 2025). Clinically, it has also been reported that “Injection of PAAG hydrogel intraarticularly into the knee has been shown to be safe with no long-lasting adverse events reported” (Cole et al., 2022).

Experts like Professor Paul Lee and the MSK Doctors team play a vital role by collecting real-world evidence from patients, helping to inform future decisions about whether Arthrosamid will become part of NHS care.

What Could Enable NHS Access in the Future?

The path to Arthrosamid’s availability on the NHS depends on new, high-quality research confirming its benefits and clarifying how it compares with existing treatments. Changing clinical guidelines to reflect emerging evidence could also encourage wider acceptance by healthcare professionals and NHS commissioners.

Furthermore, pilot programmes or NHS-based trials could provide valuable practical experience and data on safety and effectiveness in the UK setting. As a recent study notes, “Further prospective studies are needed to define its optimal use” (Aykaç et al., 2025). Patient advocacy and input from experts like Professor Paul Lee will continue to influence these developments.

Patients should maintain realistic expectations. NHS adoption is a careful balancing act, weighing evidence, cost, and overall system impact to ensure decisions benefit both individuals and the wider public.

Conclusion

In short, Arthrosamid injections are not currently offered on the NHS because more comprehensive clinical evidence, cost assessments, and safety assurances are needed. Although this treatment shows promise as a new option for knee osteoarthritis, NHS integration must be cautious, evidence-based, and in the best interests of patients and the health service.

Patients are encouraged to consult with knowledgeable professionals and organisations, such as Professor Paul Lee and MSK Doctors, to understand their treatment options and stay informed about emerging therapies. Knowing how NHS approval works helps people make confident, informed decisions and stay engaged with the latest advances in osteoarthritis care.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A systematic review of the novel compound Arthrosamid polyacrylamide (PAAG) hydrogel for treatment of knee osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(23). https://doi.org/10.1097/MD.0000000000044655
• Walmod, P. S., Kusk, P., Jøhnk, N., Ankorina‐Stark, I., & Essex, A. (2025). An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCell® GlutaNeurons. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2025.1585430